Changeflow GovPing Healthcare & Life Sciences Substituted Indazoles IRAK4 Inhibitor Patent Ap...
Routine Notice Added Final

Substituted Indazoles IRAK4 Inhibitor Patent Application

Favicon for changeflow.com USPTO Patent Applications - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The USPTO published patent application US20260092069A1 by inventors Terstiege, Schiesser, Xue, Chang, and Berggren for substituted indazoles as IRAK4 inhibitors with potential therapeutic utility. The application (No. 19343252) was filed September 29, 2025 and published April 2, 2026. IRAK4 inhibitors target inflammatory and autoimmune pathways.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The USPTO published a patent application covering chemical compounds of Formula (I) that inhibit IRAK4 (Interleukin-1 Receptor-Associated Kinase 4), along with their pharmaceutical salts. IRAK4 plays a role in innate immune signaling and inflammatory responses, making these compounds potential candidates for treating inflammatory, autoimmune, and allergic conditions. The application is classified under CPC codes C07D 487/04 with therapeutic indications A61P 11/06 (respiratory) and A61P 37/06 (immune disorders).

Pharmaceutical companies developing IRAK4 inhibitors or related anti-inflammatory therapeutics should review their pipelines for potential conflicts with the claimed compounds. Patent counsel may conduct freedom-to-operate analyses. This publication does not impose compliance deadlines or regulatory obligations—it is an informational record of a patent filing.

Archived snapshot

Apr 2, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

SUBSTITUTED INDAZOLES AS IRAK4 INHIBITORS

Application US20260092069A1 Kind: A1 Apr 02, 2026

Inventors

Ina TERSTIEGE, Stefan SCHIESSER, Yafeng XUE, Hui-Fang CHANG, Anna Ingrid Kristina BERGGREN

Abstract

The present application relates to chemical compounds of Formula (I), and pharmaceutically acceptable salts thereof, that inhibit IRAK4 and consequently have potential utility in medicine.

CPC Classifications

C07D 487/04 A61P 11/06 A61P 37/06

Filing Date

2025-09-29

Application No.

19343252

View original document →

Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 2nd, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260092069A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Pharmaceutical Research Drug Development
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Intellectual Property Healthcare

Get alerts for this source

We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!